High serum exosomal long non-coding RNA DANCR expression confers poor prognosis in patients with breast cancer

Wenbiao Shi | Xiaoyan Jin | Yuanfan Wang | Qiang Zhang | Linjun Yang

Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou City, Zhejiang Province, China

Correspondence
Linjun Yang, Department of Surgical Oncology, Taizhou Municipal Hospital, No.381 Zhongshan East Road, Jiaolong District, Taizhou City 318000, Zhejiang Province, China.
Email: yanglinjunylj@126.com

Abstract

Background: Exosomal long non-coding RNAs (IncRNAs) serve as excellent candidate biomarkers for clinical applications. The expression of differentiation antagonizing non-protein coding RNA (DANCR) has been shown to be decreased in breast cancer (BC) tissues and cell lines. However, the clinical value of circulating exosomal DANCR in BC has not been explored.

Methods: A total of 120 BC patients, 70 benign breast disease (BBD) patients, and 105 healthy women were recruited in this study. Total RNA was extracted from serum samples, and the level of serum exosomal IncRNA DANCR was evaluated by quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR).

Results: Serum exosomal IncRNA DANCR levels were significantly higher in BC patients than in BBD patients and normal controls. The diagnostic performance of serum exosomal IncRNA DANCR was good, and the combination of serum exosomal IncRNA DANCR, CA153, and CEA greatly improved the diagnostic accuracy for BC. High serum exosomal IncRNA DANCR level was associated with various clinicopathological variables including lymph node metastasis, ER status, HER2 status, and TNM stage. In addition, the BC patients in the high serum exosomal IncRNA DANCR expression group had significantly shorter 5-year overall survival time. Multivariate analysis demonstrated that serum exosomal IncRNA DANCR was an independent risk factor for BC.

Conclusion: Serum exosomal IncRNA DANCR may be a useful non-invasive biomarker for the clinical diagnosis and prognosis of BC.

Keywords
breast cancer, diagnosis, exosome, IncDANCR, prognosis

1 | INTRODUCTION

Breast cancer (BC) is the most frequent cancer among women around the world.1,2 In China, more than 272,400 newly diagnosed BC were reported, causing about 70,700 deaths in 2015. BC alone accounts for about 15% of all new cancers in women.3,4 Despite recent advances in surgical techniques and adjuvant chemotherapy, the clinical outcome of BC patients remains unfavorable due to the recurrence and metastasis.5 Early diagnosis and treatment significantly improve the prognosis of this malignancy. Cancer antigen 153 (CA153) and carcinoembryonic antigen (CEA) are the most commonly used biomarkers for BC. However, diagnostic and prognostic
accuracy of CA153 and CEA is poor. Therefore, it is urgent to identify novel, reliable biomarkers for GC diagnosis and prognosis evaluation.

Long non-coding RNAs (lncRNAs) are a class of non-coding RNAs with a length of longer than 200 nucleotides.\(^6,7\) Dysregulation of lncRNAs has been shown to play a critical role in regulating the initiation and progression of BC.\(^6,9\) For instance, OLBC15 was highly expressed in triple-negative BC, and OLBC15 promoted the BC tumorigenesis through destabilizing ZNF326.\(^10\) Exosomes are 30–100 nm nanovesicles containing many molecules, such as lncRNAs, proteins, DNA, RNA, and miRNAs.\(^11–13\) Exosomal lncRNAs are correlated with cancer tumorigenesis and progression and can be used as effective biomarkers in various types of cancer including BC. For example, compared to benign breast disease (BBD) and healthy controls, serum exosomal H19 was significantly increased in BC patients, and high serum exosomal H19 expression was strongly associated with worse clinical variables.\(^14\) Similarly, patients with BC exhibited higher serum exosomal HOTAIR levels, and overexpression of serum exosomal HOTAIR was correlated with poorer prognosis.\(^15\)

LncRNA differentiation antagonizing non-protein coding RNA (DANCR or ANCR), located on human chromosome 4, has been previously found to be involved in the initiation and the progression of BC.\(^16,17\) However, the diagnostic and prognostic value of circulating exosomal DANCR in BC has not yet been explored. Thus, this study aimed to detect the serum exosomal lncRNA DANCR levels in BC patients, BBD patients, and normal controls and analyzed its role as a potential novel biomarker for BC diagnosis and prognosis.

2 | MATERIALS AND METHODS

2.1 | Patients and samples

The current study was approved by the Ethics Committee of Taizhou Municipal Hospital. Written informed consent was obtained from all patients and healthy subjects. In this study, blood samples were obtained from 120 BC patients, 70 BBD patients, and 105 healthy volunteers. All recruited BC patients had not received any chemotherapy or radiotherapy prior to the sampling. We also collected the blood samples from all BC cases one month after their surgery. The blood samples were collected in anti-coagulative tubes and centrifuged at 1600 g for 10 min, followed by centrifugation at 16,000 g for 10 min at 4°C. The supernatant was stored at −80°C until further use. The clinical characteristics of all 120 patients with BC are summarized in Table 1.

2.2 | Exosome isolation

Total exosomes were isolated from serum with the total exosome isolation reagent (Invitrogen) according to the manufacturer’s protocol. The serum was thawed on ice at 25°C. Then, possible residual cell debris were removed by a centrifugation step at 2000 g for 30 min. Then, serum supernatant was mixed with the exosome isolation reagent, followed by incubation for at 4°C 30 min and centrifugation at 10,000 g for 10 min. The supernatant was discarded, and the exosomal pellet was resuspended in PBS for RNA extraction.

2.3 | RNA extraction and quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR)

Total exosomal RNA was extracted from serum samples with an miRNeasy Serum/Plasma Kit (QIAGEN). The RNA was quantified on a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific) and immediately reverse transcribed into cDNA. Before RNA extraction, 25 fmol/ml of synthesized cel-miR-39 (Applied Biosystems) was added as an exogenous spike in control. Then, qRT-PCR was performed with SYBR PrimeScript miRNA RT-PCR kit (Takara Biotechnology Co. Ltd) on the 7500 Real-Time PCR systems (Applied Biosystems). The relative levels of serum exosomal lncRNA DANCR were expressed using the 2^−ΔΔCt method.

2.4 | Measurement of CA153 and CEA in serum

The levels of CA153 and CEA were measured using electrochemiluminescence assays with available commercial kits.

| Table 1 Association of serum exosomal IncRNA DANCR with clinicopathological characteristics |
|-----------------|---------------|-----|-----|-----|-----|
| Parameters      | Cases         | Low | High | p   |
| Age             |               |     |      |     |
| <50             | 49            | 28  | 21   | 0.1936 |
| ≥50             | 71            | 32  | 39   |     |
| Tumor size (cm) |               |     |      |     |
| <3              | 66            | 37  | 29   | 0.1421 |
| ≥3              | 54            | 23  | 31   |     |
| PR status       |               |     |      |     |
| Positive        | 57            | 33  | 24   | 0.0999 |
| Negative        | 63            | 27  | 36   |     |
| LN metastasis   |               |     |      |     |
| Negative        | 44            | 29  | 15   | 0.0080 |
| Positive        | 76            | 31  | 45   |     |
| ER status       |               |     |      |     |
| Positive        | 47            | 30  | 17   | 0.0150 |
| Negative        | 73            | 30  | 43   |     |
| HER2 status     |               |     |      |     |
| Positive        | 39            | 28  | 11   | 0.0009 |
| Negative        | 81            | 32  | 49   |     |
| TNM stage       |               |     |      | <0.0001 |
| I/II            | 77            | 51  | 26   |     |
| III/IV          | 43            | 9   | 34   |     |
2.5 | Statistical analysis

The Mann-Whitney U and Kruskal-Wallis tests were used to compare the difference regarding the serum exosomal lncRNA DANCR expression between two or more groups. The chi-square test was performed to evaluate the associations between clinicopathological variables and serum exosomal lncRNA DANCR expression. Receiver operating characteristic (ROC) curves and the area under the curves (AUC) were applied to access diagnostic power of serum exosomal lncRNA DANCR, CA153, and CEA in BC. Kaplan-Meier analysis plus log-rank test was used for overall survival (OS) analysis. Multivariate Cox proportional hazard models were used to analyze the independent risk indicators for BC patients. All statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software Inc.). \( p < 0.05 \) was considered statistically significant.

3 | RESULTS

3.1 | Serum exosomal lncRNA DANCR was dramatically increased in BC patients

qRT-PCR was used to detect the serum exosomal lncRNA DANCR levels in all participants. Serum exosomal lncRNA DANCR levels were significantly higher in BC patients than in BBD subjects and controls \( (p < 0.001, \text{Figure 1A}) \). In addition, BC patients with positive lymph node metastasis \( (p = 0.005, \text{Figure 1B}) \), negative ER status \( (p = 0.012, \text{Figure 1C}) \), negative HER2 status \( (p < 0.001, \text{Figure 1D}) \), and advanced TNM stage \( (p < 0.001, \text{Figure 1E}) \) exhibited higher serum exosomal lncRNA DANCR levels compared with their respective controls.

3.2 | Diagnostic accuracy of serum exosomal lncRNA DNACR for BC

By ROC analysis, Figure 2A demonstrated that the AUC for serum exosomal lncRNA DANCR was 0.880, with a specificity of 82.9% and a sensitivity of 83.3%. CA153 and CEA yielded an AUC of 0.799 (specificity: 76.0%; sensitivity: 68.3%) and 0.784 (specificity: 83.8%, sensitivity: 72.5%) for discriminating BC cases from controls (Figure 2B,C). More importantly, the combination of serum exosomal lncRNA DANCR, CA153, and CEA presented further improvement with an AUC of 0.954 (specificity: 91.4%, sensitivity: 90.8%) (Figure 2D; Table 2).

3.3 | Increased serum exosomal lncRNA DANCR expression was correlated with clinical variables in BC patients

The median serum exosomal lncRNA DANCR expression was used as a cut-off value, and all 120 BC patients were classified into two groups: high serum exosomal DANCR expression group \( (n = 60) \) and low serum exosomal DANCR expression group \( (n = 60) \). As

---

**FIGURE 1**  Serum exosomal lncRNA DANCR levels were significantly higher in BC patients (A). Increased serum exosomal lncRNA DANCR expression occurred more frequently in BC patients with positive lymph node metastasis (B), negative ER status (C), negative HER2 status (D), and advanced TNM stage (E)
illustrated in Table 1, high serum exosomal lncRNA DANCR expression occurred more frequently in BC cases with positive lymph node metastasis ($p = 0.0080$), negative ER status ($p = 0.0150$), negative HER2 status ($p = 0.0009$), and advanced TNM stage ($p < 0.0001$). However, there was no significant correlation between serum exosomal lncRNA DANCR expression and age, tumor size, and PR status (all $p > 0.05$).

### 3.4 | Alteration of serum exosomal lncRNA DANCR levels following treatments

One month after surgical resection, paired blood samples were collected from all BC subjects. qRT-PCR was used to measure the serum exosomal lncRNA DANCR expression level, and we found the serum exosomal lncRNA DANCR levels were markedly reduced following surgery ($p < 0.001$, Figure 3).

### 3.5 | Serum exosomal lncRNA DANCR expression was a prognostic biomarker for BC

The Kaplan-Meier curve for OS regarding serum exosomal lncRNA DANCR expression is presented in Figure 4. Compared to BC patients with low serum exosomal lncRNA DANCR expression, patients with high serum exosomal lncRNA DANCR expression survived significantly shorter ($p = 0.0132$). Furthermore, multivariate analysis indicated that lymph node metastasis (HR = 3.12, 95% CI = 1.65–5.78, $p = 0.018$), ER status (HR = 2.75, 95% CI = 1.38–5.26, $p = 0.021$), HER2 status (HR = 3.51, 95% CI = 1.92–6.24, $p = 0.014$), TNM stage (HR = 4.75, 95% CI = 2.74–8.32, $p < 0.001$), and serum exosomal lncRNA DANCR expression (HR = 3.86, 95% CI = 2.16–6.63, $p = 0.009$) were significant independent prognostic markers for shorter OS (Table 3).

### 4 | DISCUSSION

Dysregulation of lncRNAs has been demonstrated to play major roles in breast cancer progression.18 This study enrolled a total of 120
High DANCR expression was significantly associated with worse clinical parameters and shorter survival. Thus, IncRNA DANCR expression was closely associated with worse clinical parameters of PTC patients, suggesting that IncRNA DANCR played a tumor suppressive role in PTC. The contradictory functions of IncRNA DANCR may be explained by its ambiguous role in regulation of the complex networks of oncogenes and tumor suppressors resulting in a cancer type-dependent outcome.

## 5 | CONCLUSIONS

Taken together, this study demonstrated that serum exosomal IncRNA DANCR expression was markedly elevated in patients with BC. Upregulation of serum exosomal IncRNA DANCR was closely associated with worse clinical parameters and shorter survival. Thus, serum exosomal IncRNA DANCR serves as a promising prognostic marker for BC. Meanwhile, as a result of small sample research, the analysis of larger cohorts is required to confirm the clinical role of serum exosomal IncRNA DANCR in BC.

## CONFLICT OF INTERESTS

None.

## DATA AVAILABILITY STATEMENT

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Linjun Yang

https://orcid.org/0000-0002-1987-6753

---

**TABLE 3** Multivariate analysis of overall survival in 120 BC patients

| Variables            | Hazard ratio | 95% CI    | P   |
|----------------------|--------------|-----------|-----|
| Lymph node metastasis| 3.12         | 1.65–5.78 | 0.018|
| ER status            | 2.75         | 1.38–5.26 | 0.021|
| HER2 status          | 3.51         | 1.92–6.24 | 0.014|
| TNM stage            | 4.75         | 2.74–8.32 | <0.001|
| DANCR                | 3.86         | 2.16–6.63 | 0.009|

Abbreviations: BC, breast cancer; DANCR, differentiation antagonizing non-protein coding RNA.

---

**TABLE 2** Comparison of expression levels of IncRNA DANCR in different tissues

| Variables      | Expression level |
|----------------|------------------|
| BC tissues     | Compared to normal tissues, and its overexpression was negatively associated with CRC patient survival. Upregulation of IncRNA DANCR significantly promoted carcinogenesis and metastasis via sponging miR-577. Moreover, IncRNA DANCR was remarkably increased in ovarian cancer (OC) tissues and cell lines. Overexpression of IncRNA DANCR significantly promoted OC cell proliferation, invasion, and migration through regulating IGF2 or UPF1. However, IncRNA DANCR expression was frequently lower in papillary thyroid cancer (PTC) tissues than that in adjacent normal tissues, and low IncRNA DANCR expression was closely associated with worse clinical parameters of PTC patients, suggesting that IncRNA DANCR played a tumor suppressive role in PTC. The contradictory functions of IncRNA DANCR may be explained by its ambiguous role in regulation of the complex networks of oncogenes and tumor suppressors resulting in a cancer type-dependent outcome.

**FIGURE 4** Kaplan-Meier analysis of overall survival (OS) according to serum exosomal long non-coding RNAs (lncRNAs) differentiation antagonizing non-protein coding RNA (DANCR) expression

---

**DATA AVAILABILITY STATEMENT**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**ORCID**

Linjun Yang https://orcid.org/0000-0002-1987-6753
REFERENCES

1. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-271.

2. Chuffa LGA, Carvalho RF, Justulin LA, et al. A meta-analysis of microRNA networks regulated by melatonin in cancer: Portrait of potential candidates for breast cancer treatment. J Pineal Res. 2020;69(4):e12693.

3. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.

4. Li N, Deng Y, Zhou L, et al. A novel melatonin-regulated IncRNA suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression. J Pineal Res. 2021;71(3):e12760.

5. Bai X, Jiang X, Liu Y, et al. Kruppel-like factor 9 upregulates E-cadherin transcription and represses breast cancer invasion and metastasis. Am J Cancer Res. 2021;11(7):3660-3673.

6. Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703-719.

7. Su SC, Yeh CM, Lin CW, et al. A novel melatonin-regulated IncRNA suppresses TPA-induced oral cancer cell motility through replenishing PRUNE2 expression. J Pineal Res. 2021;71(3):e12760.

8. Wei M, Wang J, He Q, Liu L, Wang Z. AC016405.5 functions as an oncogenic long non-coding RNA by regulating ERBB3 via sponging miR-22-3p in breast cancer. J Clin Lab Anal. 2021;35(9):e23952.

9. Wu J, Cai Y, Zhao G, Li M. A ten N6-methyladenosine-related long non-coding RNAs signature predicts prognosis of triple-negative breast cancer. J Clin Lab Anal. 2021;35(6):e23779.

10. Deng C, Zhang B, Zhang Y, et al. A long non-coding RNA OLBC15 promotes triple-negative breast cancer progression via enhancing ZNF326 degradation. J Clin Lab Anal. 2020;34(8):e23304.

11. Xu F, Zhong JY, Lin X, et al. Melatonin alleviates vascular calcification and ageing through exosomal miR-204/miR-211 cluster in a paracrine manner. J Pineal Res. 2020;68(3):e12631.

12. Pant S, Hilton H, Burcynski ME. The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol. 2012;83(11):1484-1494.

13. Yoon YM, Lee JH, Song KH, Noh H, Lee SH. Melatonin-stimulated exosomes enhance the regenerative potential of chronic kidney disease-derived mesenchymal stem/stromal cells via cellular prion proteins. J Pineal Res. 2020;68(3):e12632.

14. Zhong G, Wang K, Li J, Xiao S, Wei W, Liu J. Determination of serum exosomal H19 as a noninvasive biomarker for breast cancer diagnosis. Onco Targets Ther. 2020;13:2563-2571.

15. Tang S, Zheng K, Tang Y, Li Z, Zou T, Liu D. Overexpression of serum exosomal HOTAIR is correlated with poor survival and poor response to chemotherapy in breast cancer patients. J Biosci. 2019;44(2):37.

16. Zhang KJ, Tan XL, Guo L. The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription. Mol Oncol. 2020;14(2):309-328.

17. Tao W, Wang C, Zhu B, Zhang G, Pang D. IncRNA DANCR contributes to tumor progression via targeting miR-216a-5p in breast cancer: IncRNA DANCR contributes to tumor progression. Biosci Rep. 2019;39(4):BRS20181618.

18. Tian T, Wang M, Lin S, et al. The impact of IncRNA dysregulation on clinicopathology and survival of breast cancer: a systematic review and meta-analysis. Mol Ther Nucleic Acids. 2018;12:359-369.

19. Pan L, Liang W, Gu J, et al. Long noncoding RNA DANCR is activated by SALL4 and promotes the proliferation and invasion of gastric cancer cells. Oncotarget. 2018;9(2):1915-1930.

20. Zhan Y, Chen Z, Li Y, et al. Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA. J Exp Clin Cancer Res. 2018;37(1):273.

21. Chen Z, Chen X, Xie R, et al. DANCR promotes metastasis and proliferation in bladder cancer cells by enhancing IL-11-STAT3 signaling and CCND1 Expression. Mol Ther. 2019;27(2):326-341.

22. Liu Y, Zhang M, Liang L, Li J, Chen YX. Over-expression of IncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. Int J Exp Pathol. 2015;89(9):11480-11484.

23. Wang Y, Lu Z, Wang N, et al. Long noncoding RNA DANCR promotes colorectal cancer progression and metastasis via miR-577 sponging. Exp Mol Med. 2018;50(5):1-17.

24. Gao YQ, Cheng HY, Liu KF. Long non-coding RNA DANCR upregulates IGF2 expression and promotes ovarian cancer progression. Eur Rev Med Pharmacol Sci. 2019;23(9):3621-3626.

25. Pei CL, Fei KL, Yuan XY, Gong XJ. LncRNA DANCR aggravates the progression of ovarian cancer by downregulating UPF1. Eur Rev Med Pharmacol Sci. 2019;23(24):10657-10663.

26. Zhang K, Lv J, Peng X, et al. Down-regulation of DANCR acts as a potential biomarker for papillary thyroid cancer diagnosis. Biosci Rep. 2019;39(4).

How to cite this article: Shi W, Jin X, Wang Y, Zhang Q, Yang L. High serum exosomal long non-coding RNA DANCR expression confers poor prognosis in patients with breast cancer. J Clin Lab Anal. 2022;36:e24186. doi:10.1002/jcla.24186